NCT02610348View on ClinicalTrials.gov

Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

NACompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Hepatitis B
Interventions
BIOLOGICAL

DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines

Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study

BIOLOGICAL

DTaP-HB-IPV and Pneumococcal polysaccharide vaccines

Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study

Trial Locations (2)

10700

Bangkok

40002

Khon Kaen

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02610348 - Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age | Biotech Hunter | Biotech Hunter